"Isotretinoin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A topical dermatologic agent that is used in the treatment of ACNE VULGARIS and several other skin diseases. The drug has teratogenic and other adverse effects.
| Descriptor ID |
D015474
|
| MeSH Number(s) |
D02.455.326.271.665.202.495.325 D02.455.426.392.368.367.379.249.700.325 D02.455.849.131.495.325 D23.767.261.700.325
|
| Concept/Terms |
Isotretinoin- Isotretinoin
- 13-cis-Retinoic Acid
- 13 cis Retinoic Acid
|
Below are MeSH descriptors whose meaning is more general than "Isotretinoin".
Below are MeSH descriptors whose meaning is more specific than "Isotretinoin".
This graph shows the total number of publications written about "Isotretinoin" by people in this website by year, and whether "Isotretinoin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 1 | 2 | 3 |
| 1998 | 1 | 0 | 1 |
| 2000 | 0 | 1 | 1 |
| 2002 | 0 | 1 | 1 |
| 2006 | 1 | 0 | 1 |
| 2010 | 0 | 1 | 1 |
| 2013 | 1 | 0 | 1 |
| 2014 | 1 | 0 | 1 |
| 2017 | 2 | 0 | 2 |
| 2021 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Isotretinoin" by people in Profiles.
-
Poverty and Targeted Immunotherapy: Survival in Children's Oncology Group Clinical Trials for High-Risk Neuroblastoma. J Natl Cancer Inst. 2021 03 01; 113(3):282-291.
-
Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032. Clin Cancer Res. 2021 04 15; 27(8):2179-2189.
-
ASDS Guidelines Task Force: Consensus Recommendations Regarding the Safety of Lasers, Dermabrasion, Chemical Peels, Energy Devices, and Skin Surgery During and After Isotretinoin Use. Dermatol Surg. 2017 Oct; 43(10):1249-1262.
-
Double-blind, randomized phase 3 trial of low-dose 13-cis retinoic acid in the prevention of second primaries in head and neck cancer: Long-term follow-up of a trial of the Eastern Cooperative Oncology Group-ACRIN Cancer Research Group (C0590). Cancer. 2017 Dec 01; 123(23):4653-4662.
-
Isotretinoin use and celiac disease: a population-based cross-sectional study. Am J Clin Dermatol. 2014 Dec; 15(6):537-42.
-
Reply to N.-K.V. Cheung et al. J Clin Oncol. 2014 Dec 20; 32(36):4174-5.
-
Treatment of two cases with refractory, metastatic intermediate-risk neuroblastoma with isotretenoin alone or observation. Pediatr Blood Cancer. 2014 Jun; 61(6):1104-6.
-
Alleged isotretinoin-associated inflammatory bowel disease: disproportionate reporting by attorneys to the Food and Drug Administration Adverse Event Reporting System. J Am Acad Dermatol. 2013 Sep; 69(3):393-8.
-
About the benefits of immunotherapy for high-risk neuroblastoma. J Clin Oncol. 2013 Feb 10; 31(5):649-50.
-
Concomitant antibiotic usage does not augment the risk of inflammatory bowel disease with isotretinoin treatment for acne: a review of the Food and Drug Administration Adverse Event Reporting System. Eur J Clin Pharmacol. 2013 Apr; 69(4):1041-2.